Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biomet 3Q Loss Widens On Charges; Sales Grow 5%

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 04:51pm CET

("Biomet 3Q Loss Widens On Charges; Sales Grow 5%," at 7:03 a.m. EDT, misstated the hip sales increase in the sixth paragraph. The correct version follows:)

Biomet Inc.'s fiscal third-quarter loss widened on merger-related costs as strong sales for sports medicine, extremities and trauma helped drive the orthopedic medical-device maker's top-line growth.

Though privately held, Biomet's results are closely watched because the company reports earlier than larger competitors--such as Zimmer Holdings Inc. (>> Zimmer Holdings, Inc.), Stryker Corp. (SYK) and Johnson & Johnson (>> Johnson & Johnson)--and could foreshadow industry trends.

Biomet has seen its losses widen in recent quarters, weighed down by charges related to its $11.4 billion buyout in 2007 by a private-equity consortium including affiliates from The Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co. and TPG. Sales have also been weak as patients, worried about out-of-pocket costs or long absences from work to recover, opt to defer hip and knee-replacement procedures. Biomet has said it is unclear when demand will come back.

For the quarter ended Feb. 29, Biomet reported a loss of $16.5 million, compared with a loss of $11.6 million a year earlier. Excluding merger and other special items, adjusted earnings fell to $55.1 million from $63.8 million. Sales jumped 4.5% to $708.9 million.

Gross margin slipped to 69% from 69.3%.

The company, which distributes products in about 90 countries, said worldwide hip sales increased 6%, while worldwide knee sales grew 4%. Sales for sports medicine, extremities and trauma were up 16%, while the spine and bone healing segment saw a 5% drop.

U.S. sales grew 5% while Europe sales rose 2.1%. International sales, which include Canada, South America, Mexico and the Asia-Pacific region, jumped 7.2%.

Last week, Biomet made a binding offer to acquire the global trauma business of Johnson & Johnson's DePuy Orthopaedics Inc. for about $280 million in cash, a deal the company said would greatly expand its sports, extremities and trauma business. Biomet also recently agreed to pay $23 million in penalties to settle U.S. allegations that it bribed doctors in Brazil, China and other countries over a period of years.

--By Anne Pallivathuckal and Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stocks mentioned in the article : Zimmer Holdings, Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
02/16 ZIMMER BIOMET : Announces the International Release of the Innovative Subchondro..
02/10 ZIMMER BIOMET : slicing 1% of its US jobs Warsaw company mum on actual number to..
02/09 ZIMMER BIOMET : Technical Reports on Medical Equipment Equities -- Edwards Lifes..
02/09 Smith & Nephew hurt by tough markets in China and Gulf states
02/07 ZIMMER BIOMET : Feb 7, 2017 Zimmer Biomet Announces the International Release of..
02/07 ZIMMER BIOMET : Feb 7, 2017 Zimmer Biomet Holdings to Present at the LEERINK Par..
02/01 ZIMMER BIOMET : Feb 1, 2017 Zimmer Biomet Announces FDA Approval of Expanded 26-..
01/31DJZIMMER BIOMET : Hip, Knee Businesses Drive Results
01/31 ZIMMER BIOMET : beats 4Q profit forecasts
01/31 ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition, Fi..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
02/21DJMEDTRONIC : Earnings Fall, Sales Rise -- Update
02/21 MEDTRONIC : sales, profit beat estimates; shares rise
02/21DJMEDTRONIC : Earnings Fall, Sales Rise
02/16 STRAUMANN : on hunt for 3D printer partner, could take stake - CEO
02/09 Smith & Nephew hurt by tough markets in China and Gulf states
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
02/23 Back To The Future With Wright Medical
02/13 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 87 Increases Expected By April 30
02/09 VALUATION DASHBOARD : Healthcare - Update
01/31 Zimmer Biomet Holdings' (ZBH) CEO David Dvorak on Q4 2016 Results - Earnings ..
01/31 Zimmer Biomet Holdings revenues up 4%; non-GAAP EPS up 2% in Q4; updates 2017..
Advertisement
Financials ($)
Sales 2017 7 886 M
EBIT 2017 2 525 M
Net income 2017 1 165 M
Debt 2017 9 260 M
Yield 2017 0,84%
P/E ratio 2017 23,07
P/E ratio 2018 16,93
EV / Sales 2017 4,13x
EV / Sales 2018 3,86x
Capitalization 23 311 M
More Financials
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 134 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Robin T. Barney Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS..12.77%23 311
MEDTRONIC PLC11.78%110 860
BAXTER INTERNATIONAL I..13.64%27 408
C R BARD INC8.49%17 557
HOYA CORPORATION3.13%17 545
DENTSPLY SIRONA INC8.18%14 418
More Results